Search
Search Results
-
Investigation of fingolimod-induced lymphocyte sequestration on inflammatory response and neurological damages after cardiac arrest
BackgroundA sepsis-like syndrome is known to occur after cardiac arrest, leading to cerebral infiltration by white blood cells (WBC). We hypothesized...
-
Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review
Purpose of ReviewThe treatment of multiple sclerosis has been revolutionised by disease-modifying therapies including fingolimod. However, these...
-
Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
IntroductionSiponimod, a potent and selective sphingosine-1-phosphate (S1P 1,5 ) agonist, is the only therapeutic agent that has shown efficacy...
-
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
BackgroundFingolimod, natalizumab, and ocrelizumab are commonly used in the second-line treatment of relapsing-remitting multiple sclerosis (RRMS)....
-
A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection
Fingolimod is approved in Italy as a second-line therapy for relapsing–remitting multiple sclerosis (RRMS). Discontinuation of fingolimod may elevate...
-
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to...
-
Multiple Sclerosis Relapses Following Cessation of Fingolimod
BackgroundThere is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is...
-
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod
IntroductionFingolimod is the first approved oral therapy for relapsing–remitting multiple sclerosis (RRMS). The present study aimed to further...
